These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 30417231)

  • 1. Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial : The CLAU Randomized Trial Long-Term Outcome.
    De Haro J; Bleda S; Gonzalez-Hidalgo C; Michel I; Acin F
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):203-209. PubMed ID: 30417231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease.
    De Haro J; Bleda S; Varela C; Esparza L; Acin F;
    Am J Cardiol; 2016 Jan; 117(2):295-301. PubMed ID: 26651453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
    Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher long-term cardiovascular morbidity after open surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes - a nationwide observational cohort study.
    Dakhel A; Zarrouk M; Ekelund J; Acosta S; Miftaraj M; Eliasson B; Svensson AM; Gottsäter A
    Vasa; 2021 Apr; 50(3):224-230. PubMed ID: 33334201
    [No Abstract]   [Full Text] [Related]  

  • 7. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
    Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilostazol and outcome in outpatients with peripheral artery disease.
    Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M;
    Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Behr J; Brown KK; du Bois RM; Lancaster L; de Andrade JA; Stähler G; Leconte I; Roux S; Raghu G
    Am J Respir Crit Care Med; 2008 Jan; 177(1):75-81. PubMed ID: 17901413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
    Kurklinsky AK; Levy M
    Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
    Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
    J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
    Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
    Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year prognosis after endovascular therapy in claudicant patients with iliofemoral artery disease.
    Miura T; Soga Y; Miyashita Y; Iida O; Kawasaki D; Hirano K; Suzuki K; Ikeda U
    J Endovasc Ther; 2014 Jun; 21(3):381-8. PubMed ID: 24915585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
    Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
    J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
    Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
    J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.